BIOA · BioAge Labs, Inc.

Track BIOA — free

$4.84 -0.51 (-9.53%) At close · Oct 16

Russell 2000 member Rebalance outlook locked

Market Cap

$222.14M

45.90M

Volume · Oct 16 868.26K Avg daily vol (3M) 924.65K

Up next

Latest filing: 10-Q

filed Aug 5, 2026

Q1 2026 earnings call transcript

call held Apr 21, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$10.36M

Trailing 12 months

Net income (TTM)

−$94.46M

Trailing 12 months

Revenue growth YoY

+1.6%

Year over year

Operating margin

-1,026.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-39.7%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$278.45M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+25.1%

Year over year · more shares

Price change (1Y)

-5.3%

Trailing year

Short interest

7.1%

Latest settlement · 3.9 days to cover

View all 115 metrics

Quarterly results

Revenue Net income Net loss

· $0 −$13.58M '24 Q2 · $0 −$23.41M '24 Q3 · $1.45M −$12.93M '25 Q1 · $2.41M −$21.56M '25 Q2 · $2.05M −$20.17M '25 Q3 · $3.08M −$25.94M '25 Q4* ▲91% $2.77M −$22.25M '26 Q1 LATEST ▲1.6% $2.45M −$26.10M '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 20 · elevated Equity put/call 0.65

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −70%

below

Price vs 50-day avg −43%

below

RSI (14) 17

oversold

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −40%

trailing

6-month return −73%

trailing

YTD return −63%

this year

Relative strength −80%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $8 › 200d $16 — 200d above 50d

Institutional flow Accumulating

9 of 150 funds reported for Sep 30 · net +301.5K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

7.13% of float · ▲ +6.5% MoM · 3.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

150 holders — near 2-yr high, broad support

Squeeze score 56

elevated · 0–100

Fundamentals

Strong

EPS growth +66%

Y/Y

Free cash flow $-82.3M

Balance sheet $186.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 109%

annualized · 1-yr

Max drawdown −81%

past year

ATR 9.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−70% Bearish

Price vs 50-day avg

−43% Bearish

RSI (14)

17 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $8 › 200d $16 — 200d above 50d

Institutional flow Accumulating

9 of 150 funds reported for Sep 30 · net +301.5K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

7.13% of float · ▲ +6.5% MoM · 3.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

150 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $5 · 0% Range high $25

vs 200-day avg -70% vs 50-day avg -43%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BIOA BioAge Labs, Inc. this stock	$222.14M	-63.4%	—	—	7.1%
TAK Takeda Pharmaceutical Co Ltd	$62.84B	+26.2%	—	—	0.1%
GALDY Galderma Group AG/ADR	$49.52B	+2.5%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$48.36B	+33.0%	+4.3%	68.0	2.6%
HLN Haleon plc	$44.55B	+0.2%	—	—	0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

148

% held: 85.0%
Reported: 9 of 150
Top holder: a16z Capital Management,…

Held Float

View

Held by Funds

Fund positions

167

View

Short & Settlement

Short Interest Rising

Shares short

3.3M

Days to cover: 3.9d
Change: +200.4K sh

View

Short Volume

Short vol %

44%

As of: Oct 16, 2026

Short Total

View

Fails to Deliver

FTD shares

6.5K

Value: $45.7K
As of: Sep 28, 2026

View

Off-Exchange

Off-exchange %

45.0%

Week of: Sep 7, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$9.0M

Net income (FY): $-80.6M
EPS diluted: $-2.24

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 2, 2026
This year: 15

View

Proposed Sales

Value

$509.2K

Shares: 20.2K
Filed: Jun 30, 2026

View

Exempt Offerings

Offering

$194.4M

Filed: Feb 13, 2024

View

Earnings & Events

Webcasts

Last webcast

Sep 30, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
BIOA	-23.7%	-40.0%	-73.2%	-31.7%	-63.4%
SPY	-2.0%	+0.2%	+6.7%	+0.1%	+11.9%
vs SPY	-21.7%	-40.2%	-79.9%	-31.8%	-75.4%

Key facts CIK 1709941 CUSIP 09077V100 13F (30d) 8 filings 8 filers Visit website Investor relations

BIOA · BioAge Labs, Inc.

Price & Indicators

Up next

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance